WHO issues guidelines for GLP-1 receptor agonists in obesity

The World Health Organization introduced guidelines to aid clinicians in the use of glucagon-like peptide-1 receptor agonists to treat obesity.

The guidelines come as public health systems across the world work to incorporate GLP-1 receptor agonists into their care strategies, according to a news article from Reuters. The WHO recently recognized obesity — defined as a body mass index of 30 or greater — as a chronic condition.

The organization’s new recommendations indicate that the drugs can be implemented as part of long-term treatment plans alongside healthy diets and regular physical activity in nonpregnant adult patients.

Clinicians should factor in the possible risks of long-term treatment at higher doses as well as drug costs and availability when deciding whether to prescribe GLP-1 receptor agonists among patients with obesity.

Read more: Reuters

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.